Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Острый лимфобластный лейкоз

Список литературы

  1. Pui C.-H. Treatment of acute leukemias. New directions for clinical research. New Jersey, Humana Press Inc., 2003.
  2. Rabin K.R., Gramatges M.M., Margolin J.F. Acute lymphoblastic leukemia // Principles and Practice of Pediatric Oncology, 7th ed. 2015. P. 463–497.
  3. Мякова Н.В. Острый лимфобластный лейкоз. // Практическое руководство по детским болезням. Под ред. Коколиной В.Ф., Румянцева А.Г., Том IV – Гематология/ онкология детского возраста. Под ред. А.Г.Румянцева, Е.В.Самочатовой. М, Медпрактика-М. 2004. P. 518–537.
  4. Карачунский А.И., Мякова Н.В. Острый лимфобластный лейкоз // Педиатрия: национальное руководство в 2 т. М, ГЭОТАР-Медиа. 2009. P. 944–955.
  5. Hunger S.P., Mullighan C.G. Acute lymphoblastic leukemia in children // New England Journal of Medicine. Massachussetts Medical Society, 2015. Vol. 373, № 16. P. 1541–1552.
  6. Cooper S.L., Brown P.A. Treatment of pediatric acute lymphoblastic leukemia // Pediatric Clinics of North America. W.B. Saunders, 2015. Vol. 62, № 1. P. 61–73.
  7. Heerema-McKenney A., Cleary M., Arber D. Pathology and molecular diagnosis of leukemias and lymphomas // Principles and Practice of Pediatric Oncology. 7th ed. Philadelphia, Pa: Lippincott Williams and Wilkins. 2015. P. 113–130.
  8. Wenzinger C., Williams E., Gru A.A. Updates in the pathology of precursor lymphoid neoplasms // The revised Fourth edition of the WHO Classification of tumors of hematopoietic and lymphoid tissues. Curr Hematol Malig Rep. 2018. P. 275–288.
  9. Wang S., He G. 2016 Revision to the WHO classification of acute lymphoblastic leukemia // J. Transl. Intern. Med. Walter de Gruyter GmbH, 2017. Vol. 4, № 4. P. 147–149.
  10. Swerdlow S.H. et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon, France: International Agency for Research in Cancer (IARC) / ed. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H T.J. 2017. 585 p.
  11. Bene M.C. et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). // Leukemia. 1995. Vol. 9, № 10. P. 1783–1786.
  12. Coustan-Smith E. et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia // Lancet Oncol. 2009. Vol. 10, № 2. P. 147–156.
  13. Новикова И.А. et al. Стандарт российско-белорусской кооперативной группы по иммунофенотипированию острого лимфобластного лейкоза у детей // Онкогематология. 2018. Vol. 13(1). P. 73–82.
  14. Dworzak M.N. et al. AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of Pediatric acute lymphoblastic leukemia // Cytom. Part B - Clin. Cytom. John Wiley and Sons Inc., 2018. Vol. 94, № 1. P. 82–93.
  15. Литвинов Д.В. et al. Лечение острого лимфобластного лейкоза у детей: современные возможности и нерешенные проблемы // Доктор.Ру. 2015. Vol. 10(111). P. 30–37.
  16. Pui C.H. Toward a total cure for acute lymphoblastic leukemia // Journal of Clinical Oncology. 2009. Vol. 27, № 31. P. 5121–5123.
  17. Vrooman L.M., Silverman L.B. Childhood acute lymphoblastic leukemia: Update on prognostic factors // Current Opinion in Pediatrics. 2009. Vol. 21, № 1. P. 1–8.
  18. Hunger S.P. et al. The thirteenth international childhood acute lymphoblastic leukemia workshop report: La Jolla, CA, USA, December 7-9, 2011 // Pediatr. Blood Cancer. 2013. Vol. 60, № 2. P. 344–348.
  19. Bürger B. et al. Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: Significance of low leukocyte counts with blasts or traumatic lumbar puncture // J. Clin. Oncol. 2003. Vol. 21, № 2. P. 184–188.
  20. Румянцев А.Г., Масчан А.А., Самочатова Е.В. Сопроводительная терапия и контроль инфекций при гематологических и онкологических заболеваниях. 2009. 448 p.
  21. Nellis M.E., Goel R., Karam O. Transfusion Management in Pediatric Oncology Patients // Hematology/Oncology Clinics of North America. W.B. Saunders, 2019. Vol. 33, № 5. P. 903– 913.
  22. Schultz K.R. et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: A combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG) // Blood. 2007. Vol. 109, № 3. P. 926–935.
  23. Gaynon P.S. et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. // Cancer. 1997. Vol. 80, № 9. P. 1717–1726.
  24. Gao J., Liu W.J. Prognostic value of the response to prednisone for children with acute lymphoblastic leukemia: A meta-analysis // Eur. Rev. Med. Pharmacol. Sci. 2018. Vol. 22, № 22. P. 7858–7866.
  25. Soverini S., Bassan R., Lion T. Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: Recent advances and remaining challenges // Journal of Hematology and Oncology. BioMed Central Ltd., 2019. Vol. 12, № 1. P. 1–14.
  26. Pérez-Losada J., Gutiérrez-Cianca N., Sánchez-García I. Philadelphia-positive B-cell acute lymphoblastic leukemia is initiated in an uncommitted progenitor cell // Leukemia and Lymphoma. Harwood Academic Publishers GmbH, 2001. Vol. 42, № 4. P. 569–576.
  27. Wu J. et al. [Identification of gene rearrangements in childhood leukemia by using a multiplex polymerase chain reaction-microarray approach]. // Zhongguo shi yan xue ye xue za zhi. 2009. Vol. 17, № 4. P. 908–912.
  28. Borowitz M.J. et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: A Children’s Oncology Group study // Blood. 2008. Vol. 111, № 12. P. 5477–5485.
  29. Conter V. et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: Results in 3184 patients of the AIEOP-BFMALL 2000 study // Blood. 2010. Vol. 115, № 16. P. 3206–3214.
  30. Schrappe M. et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: Results of the AIEOP-BFM-ALL 2000 study // Blood. 2011. Vol. 118, № 8. P. 2077–2084.
  31. Румянцев А.Г. Эволюция лечения острого лимфобластного лейкоза у детей // Педиатрия. 2016. Vol. 95(4). P. 11–22.
  32. Румянцева Ю.В., Карачунский А.И., Румянцев А.Г. Оптимизация терапии острого лимфобластного лейкоза у детей в России // Педиатрия. 2009. Vol. 87(4). P. 19–28.
  33. Sramkova L. et al. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia // Pediatr. Blood Cancer. 2007. Vol. 48, № 1. P. 93–100.
  34. Shen Z. et al. Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta- analysis // BMC Cancer. 2018. Vol. 18, № 1. P. 755.
  35. Sanchez-Garcia J. et al. Quantification of minimal residual disease levels by flow cytometry at time of transplant predicts outcome after myeloablative allogeneic transplantation in ALL // Bone Marrow Transplant. 2013. Vol. 48, № 3. P. 396–402.
  36. McCarville M.B. Malignant pulmonary and mediastinal tumors in children: Differential diagnoses // Cancer Imaging. BioMed Central, 2010. Vol. 10, № SPEC. ISS. A. P. S35.
  37. Balduzzi A. et al. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: Comparison by genetic randomisation in an international prospective study // Lancet. 2005. Vol. 366, № 9486. P. 635–642.
  38. Schrauder A. et al. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: Results from ALL-BFM 90 and 95 // J. Clin. Oncol. 2006. Vol. 24, № 36. P. 5742– 5749.
  39. Ribera J.M. et al. Comparison of intensive chemotherapy, allogeneic, or autologous stem-cell transplantation as postremission treatment for children with very high risk acute lymphoblastic leukemia: PETHEMA ALL-93 trial // J. Clin. Oncol. 2007. Vol. 25, № 1. P. 16–24.
  40. Duval M. et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure // J. Clin. Oncol. 2010. Vol. 28, № 23. P. 3730–3738.
  41. Румянцева Ю.В. et al. Профилактика нейролейкемии у детей с острым лимфобластным лейкозом: стратегия Москва-Берлин // Вопросы гематологии/ онкологии и иммунопатологии в педиатрии. 2009. Vol. 8 (2). P. 5–14.
  42. Pui C.H. Central nervous system disease in acute lymphoblastic leukemia: prophylaxis and treatment. // Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2006. P. 142–146.
  43. Pui C.H., Evans W.E. A 50-year journey to cure childhood acute lymphoblastic leukemia // Semin. Hematol. 2013. Vol. 50, № 3. P. 185–196.
  44. Карачунский А.И. et al. ALL-MB 2015. Протокол кооперативной группы Москва- Берлин по исследованию острого лимфобластного лейкоза у детей. Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева. Версия 10.10.2015 [Electronic resource]. 2015. P. 244. URL: http://www.fnkc.ru/docs/ALLMB2015.pdf.
  45. Stary J. et al. Intensive chemotherapy for childhood acute lymphoblastic leukemia: Results of the randomized intercontinental trial ALL IC-BFM 2002 // J. Clin. Oncol. American Society of Clinical Oncology, 2014. Vol. 32, № 3. P. 174–184.
  46. Karachunskiy A. et al. Results of the first randomized multicentre trial on childhood acute lymphoblastic leukaemia in Russia // Leukemia. Nature Publishing Group, 2008. Vol. 22, № 6. P. 1144–1153.
  47. Румянцева Ю.В. et al. Эффективность протокола ALL-МВ-2002 у детей с острым лимфобластным лейкозом // Терапевтический архив. 2010. Vol. 7. P. 11–20.
  48. Möricke A. et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000 // Leukemia. 2010. Vol. 24, № 2. P. 265–284.
  49. Фукс О.Ю. et al. Ранний ответ на терапию при использовании ПЭГ-аспарагиназы в циторедуктивной фазе лечения острого лимфобластного лейкоза // Гематология и траснфузиология. 2007. Vol. 52(6). P. 22–26.
  50. Kumar K. et al. L-asparaginase: An effective agent in the treatment of acute lymphoblastic leukemia // Leukemia and Lymphoma. Informa Healthcare, 2014. Vol. 55, № 2. P. 256–262.
  51. Schrappe M. et al. Outcomes after induction failure in childhood acute lymphoblastic leukemia // N. Engl. J. Med. Massachussetts Medical Society, 2012. Vol. 366, № 15. P. 1371– 1381.
  52. Richards S. et al. Systematic review and meta-analysis of randomized trials of central nervous system directed therapy for childhood acute lymphoblastic leukemia. [Review] [Erratum appears in Pediatr Blood Cancer. 2013 Oct;60(10):1729 Note: Attarbarschi, A [corrected to Atta // Pediatr. Blood Cancer. Vol. 60, № 2. P. 185–195.
  53. Pui C.-H., Howard S.C. Current management and challenges of malignant disease in the CNS in paediatric leukaemia // Lancet Oncol. 2008. Vol. 9, № 3. P. 257–268.
  54. Pui C.H. et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation // N. Engl. J. Med. Massachussetts Medical Society, 2009. Vol. 360, № 26. P. 2730– 2741.
  55. Джаныбекова И.А. Интратекальная терапия при острой лимфобластной лейкемии и нейролейкемии у детей // Научные результаты биомедицинских исследований. 2017. Vol. 3, № 3. P. 18–30.
  56. Pui C.-H. Toward optimal central nervous system-directed treatment in childhood acute lymphoblastic leukemia. // J. Clin. Oncol. 2003. Vol. 21, № 2. P. 179–181.
  57. Leoni V., Biondi A. Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia // Haematologica. Ferrata Storti Foundation, 2015. Vol. 100, № 3. P. 295.
  58. Bernt K.M., Hunger S.P. Current concepts in pediatric Philadelphia chromosome- positive acute lymphoblastic leukemia // Frontiers in Oncology. Frontiers Research Foundation, 2014. Vol. 4 MAR.
  59. Schultz K.R., Bowman W.P., Aledo A. Continuous dosing Imatinib with intensive chemotherapy gives equivalent outcomes to allogeneic BMT for Philadelphia chromosome- positive (Phю) acute lymphoblastic leukemia (ALL) with longer term follow up: Updated Results of Children’s Oncology Group (COG) // Pediatr. Blood Cancer. 2010. Vol. 54. P. 788.
  60. Schultz K.R. et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s oncology group study AALL0031 // Leukemia. Nature Publishing Group, 2014. Vol. 28, № 7. P. 1467–1471.
  61. Short N.J. et al. Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia? // Best Practice and Research: Clinical Haematology. Bailliere Tindall Ltd, 2017. Vol. 30, № 3. P. 193–200.
  62. Biondi A. et al. Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial // Lancet Haematol. Elsevier Ltd, 2018. Vol. 5, № 12. P. e641–e652.
  63. Shen S. et al. Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial // JAMA Oncology. American Medical Association, 2019. Vol. 6, № 3. P. 358–366.
  64. Hijiya N. et al. Pharmacokinetics of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia or acute lymphoblastic leukemia // Clin. Cancer Res. American Association for Cancer Research Inc., 2020. Vol. 26, № 4. P. 812–820.
  65. Porkka K. et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system philadelphia chromosome positive leukemia // Blood. American Society of Hematology, 2008. Vol. 112, № 4. P. 1005–1012.
  66. Chiaretti S., Messina M., Foà R. BCR/ABL1–like acute lymphoblastic leukemia: How to diagnose and treat? // Cancer. John Wiley and Sons Inc., 2019. Vol. 125, № 2. P. 194–204.
  67. Khan M., Siddiqi R., Tran T.H. Philadelphia chromosome-like acute lymphoblastic leukemia: A review of the genetic basis, clinical features, and therapeutic options // Seminars in Hematology. W.B. Saunders, 2018. Vol. 55, № 4. P. 235–241.
  68. Roberts K.G. Why and how to treat Ph-like ALL? // Best Practice and Research: Clinical Haematology. Bailliere Tindall Ltd, 2018. Vol. 31, № 4. P. 351–356.
  69. Kotb A. et al. Philadelphia-like acute lymphoblastic leukemia: diagnostic dilemma and management perspectives // Experimental Hematology. Elsevier Inc., 2018. Vol. 67. P. 1–9.
  70. Pui C.H. et al. Philadelphia Chromosome–like Acute Lymphoblastic Leukemia // Clinical Lymphoma, Myeloma and Leukemia. Elsevier Inc., 2017. Vol. 17, № 8. P. 464–470.
  71. Ding Y.Y. et al. Clinical efficacy of ruxolitinib and chemotherapy in a child with philadelphia chromosome-like acute lymphoblastic leukemia with GOLGA5-JAK2 fusion and induction failure // Haematologica. Ferrata Storti Foundation, 2018. Vol. 103, № 9. P. e427– e431.
  72. Richards S. et al. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukemia: overview of 42 trials involving 12 000 randomised children // Lancet. 1996. Vol. 347. P. 1783–1788.
  73. Schmiegelow K. et al. Mercaptopurine/methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: Clinical facts and fiction // Journal of Pediatric Hematology/Oncology. Lippincott Williams and Wilkins, 2014. Vol. 36, № 7. P. 503–517.
  74. Yetgin S. et al. Systematic review of the addition of vincristine plus steroid pulses in maintenance treatment for childhood acute lymphoblastic leukaemia - an individual patient data meta-analysis involving 5659 children // Br. J. Haematol. Blackwell Publishing Ltd, 2010. Vol. 149, № 5. P. 722–733.
  75. Nagatoshi Y. et al. Randomized trial to compare LSA2L2-type maintenance therapy to daily 6-mercaptopurine and weekly methotrexate with vincristine and dexamethasone pulse for children with acute lymphoblastic leukemia // Pediatr. Blood Cancer. 2010. Vol. 55, № 2. P. 239–247.
  76. Shukla N. et al. Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia // Pediatr. Blood Cancer. 2014. Vol. 61, № 3. P. 431–435.
  77. Miano M. et al. Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients // Leuk. Lymphoma. 2012. Vol. 53, № 9. P. 1693–1698.
  78. Gossai N. et al. A clofarabine-based bridging regimen in patients with relapsed ALL and persistent minimal residual disease (MRD) // Bone Marrow Transplant. 2014. Vol. 49, № 3. P. 440–442.
  79. Liu A.P. et al. Refractory acute lymphoblastic leukemia in Chinese children: bridging to stem cell transplantation with clofarabine, cyclophosphamide and etoposide // Ann Hematol. 2016. Vol. 95(3). P. 501–507.
  80. Patrick K., Vora A. Update on biology and treatment of T-cell acute lymphoblastic leukaemia // Current Opinion in Pediatrics. Lippincott Williams and Wilkins, 2015. Vol. 27, № 1. P. 44–49.
  81. Winter S.S. et al. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children’s Oncology group Study AALL0434 // Pediatr. Blood Cancer. John Wiley and Sons Inc., 2015. Vol. 62, № 7. P. 1176–1183.
  82. Hefazi M., Litzow M.R. Recent Advances in the Biology and Treatment of T Cell Acute Lymphoblastic Leukemia // Current Hematologic Malignancy Reports. Current Science Inc., 2018. Vol. 13, № 4. P. 265–274.
  83. Zwaan C.M. et al. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study // Br. J. Haematol. 2017. Vol. 179, № 2. P. 284–293.
  84. Dunsmore K.P. et al. Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: A report from the Children’s Oncology Group // J. Clin. Oncol. 2012. Vol. 30, № 22. P. 2753–2759.
  85. Ribera J.M. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia // Expert Review of Hematology. Taylor and Francis Ltd, 2017. Vol. 10, № 12. P. 1057–1067.
  86. Algeri M. et al. Current and future role of bispecific T-cell engagers in pediatric acute lymphoblastic leukemia // Expert Review of Hematology. Taylor and Francis Ltd, 2018. Vol. 11, № 12. P. 945–956.
  87. Von Stackelberg A. et al. Phase I/Phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia // J. Clin. Oncol. American Society of Clinical Oncology, 2016. Vol. 34, № 36. P. 4381–4389.
  88. Yu J., Wang W., Huang H. Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin’s lymphoma: a systemic review and meta-analysis // Hematology. NLM (Medline), 2019. Vol. 24, № 1. P. 199–207.
  89. Coiffier B. et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: An evidence-based review // Journal of Clinical Oncology. 2008. Vol. 26, № 16. P. 2767–2778.
  90. Cairo M.S. et al. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: An expert TLS panel consensus // Br. J. Haematol. 2010. Vol. 149, № 4. P. 578–586.
  91. Agrawal A.K., Chang P.P., Feusner J. Twice weekly pneumocystis jiroveci pneumonia prophylaxis with trimethoprim-sulfamethoxazole in pediatric patients with acute lymphoblastic leukemia // J. Pediatr. Hematol. Oncol. 2011. Vol. 33, № 1.
  92. Schrøder H. et al. Antibacterial prophylaxis with trimethoprim-sulfamethoxazole during induction treatment for acute lymphoblastic leukemia // Dan. Med. Bull. 2001. Vol. 48, № 4. P. 275–277.
  93. Stern A. et al. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients // Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd, 2014. Vol. 2014, № 10. P. CD005590.
  94. Lehrnbecher T. et al. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update // Journal of Clinical Oncology. American Society of Clinical Oncology, 2017. Vol. 35, № 18. P. 2082–2094.
  95. Pui C.H. et al. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia // N. Engl. J. Med. 1997. Vol. 336, № 25. P. 1781–1787.
  96. Kaya Z., Belen F.B., Akyürek N. Granulocyte Colony Stimulating Factor Induced Sweet’s Syndrome Following Autologous Transplantation in a Child with Relapsed Acute Myeloblastic Leukemia // Indian J. Hematol. Blood Transfus. Springer India, 2014. Vol. 30, № Suppl 1. P. 376–378.
  97. Hill F.G.H. et al. Successful treatment without cranial radiotherapy of children receiving intensified chemotherapy for acute lymphoblastic leukaemia: Results of the risk- stratified randomized central nervous system treatment trial MRC UKALL XI (ISRC TN 16757172) // Br. J. Haematol. 2004. Vol. 124, № 1. P. 33–46.
  98. Kelly M.J. et al. Cranial radiation for pediatric T-lineage acute lymphoblastic leukemia: A systematic review and meta-analysis // American Journal of Hematology. Wiley-Liss Inc., 2014. Vol. 89, № 10. P. 992–997.
  99. Vora A. et al. Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy // J. Clin. Oncol. American Society of Clinical Oncology, 2016. Vol. 34, № 9. P. 919–926.
  100. Paul K.L. Rehabilitation and exercise considerations in hematologic malignancies. // Am. J. Phys. Med. Rehabil. 2011. Vol. 90, № 5 Suppl 1. P. S88-94.
  101. European Physical and Rehabilitation Medicine Bodies Alliance. White book on physical and rehabilitation medicine in Europe (3th Edition): Chaper 1: Definition an conceps of PRM // Eur. J. Phys. Rehabil. Med. 2018. Vol. 54, № 2. P. 156–165.
  102. Angle-Zahn A. Methotrexate for Use in Pediatric Populations // Second Meeting of the Subcommittee of the Expert Committee on the Selection and Use of Essential Medicines. 2008. P. 12.
  103. Fleischer G. Sodium methotrexste // Physician Desk Reference : A Concise Drug Guide for Pediatrics. 2007. P. 214–215.
  104. Harms D.O. et al. Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: Results of the randomized trial COALL-92 // Blood. 2003. Vol. 102, № 8. P. 2736–2740.

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*